U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07439094) titled 'A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer' on Feb. 13.
Brief Summary: This is a Phase 1/2a open-label multicenter study to evaluate the safety, efficacy, and pharmacokinetics of CKD-703 in Advanced c-Met Expressing Solid Tumors, and in MET-Amplified and c-Met Overexpressing Non-Small Cell Lung Cancer.
CKD-703 is composed of a c-Met-targeting monoclonal antibody (mAb) coupled to a cytotoxic payload consisting of the anti-microtubule drug monomethyl auristatin E (MMAE); thus, CKD-703 is a novel ADC offering a highly targeted approach with potential improvement of efficacy while reducing...